Provided by Tiger Trade Technology Pte. Ltd.

Repare Therapeutics Inc.

2.14
-0.0100-0.47%
Volume:1.55M
Turnover:3.32M
Market Cap:91.99M
PE:-1.26
High:2.20
Open:2.16
Low:2.13
Close:2.15
52wk High:4.00
52wk Low:0.8900
Shares:42.99M
Float Shares:22.72M
Volume Ratio:3.49
T/O Rate:6.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6944
EPS(LYR):-1.9969
ROE:-49.78%
ROA:-29.72%
PB:0.80
PE(LYR):-1.07

Loading ...

Mar 02, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 26, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Feb 16, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 25, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Nov 12, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2020

Major Issues Report

8-K - Current report
Aug 13, 2020

Major Issues Report

8-K - Current report
Aug 13, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 07, 2020

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Jul 06, 2020

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Jun 30, 2020

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jun 26, 2020

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Jun 24, 2020

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Jun 23, 2020

Major Issues Report

8-K - Current report
Jun 19, 2020

[Supp]Public Prospectus

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses